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Hyperprolactinaemia and Antipsychotic Drug Use: The
Benefits of Prolactin Screening for Mental Health
Patients
Michael Shaw
Abstract:
Hyperprolactinaemia is associated with drugs used in the field of Mental
Health to treat psychosis (antipsychotic).
This has been found to be affecting a significant number of service users
taking this medication. Hyperprolactinaemia causes endocrine disturbances
including sexual dysfunction and amenorrhea and infertility. However, in
the longer term service users are at risk of some disabling conditions such
as osteoporosis.
As part of our ongoing medication management work, early detection of
hyperprolactinaemia enables safer use of antipsychotic drugs.
Keywords: Prolactin elevation, Psychosis, Antipsychotic Drugs,
Medication Management.
Introduction
Antipsychotic drug use has for decades been associated with impaired
sexual functioning. (Shader and Grinspoon, 1967). A recent survey
showed that at least one symptom of sexual dysfunction was reported by
82% of men and 96% of women who had a diagnosis of schizophrenia
(MacDonald, 2003).
It is my experience as a Community Mental Health Nurse working in a
specialist Community Mental Health Team for Medication Management that
sexual dysfunction is extensive for individuals prescribed antipsychotic
drugs.
When I was appointed to the post of Team Leader (Community Treatment
Team) in 1998 we began systematically reviewing side effect profiles of all
individuals prescribed these drugs and although I was surprised by the
number of service users who reported sexual dysfunction, I was even more
surprised by the amount of people who, until this time, had not reported the
problems they were having and the subsequent level of distress they were
experiencing. For many, embarrassment was a key factor in “keeping
quiet”. Once this initial embarrassment was sensitively addressed, people
often stated that they felt relieved that they now had an arena to talk about
this problem and that the distress they were experiencing was taken
seriously.
For individuals who already had a psychiatric diagnosis that erodes their
self esteem and level of self confidence, the treatment they were receiving
in many cases further contributed to the reduction of their self worth, which
will inhibit recovery from psychosis and rehabilitation into the wider
community. Having realised the extent of the problem within my locality, I
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began to examine the research published within this area and realised that
antipsychotic drugs induced sexual dysfunction is directly linked to elevated
prolactin levels.
A definite cause and effect scenario was reported in the literature. I was
also shocked to discover that hyperprolactinaemia has a causal link to
osteoporosis (Meaney and O’Keene, 2003). Not only were individuals
experiencing the shorter term misery of sexual dysfunction, but were at risk
of a longer term disabling condition.
The Role of Prolactin
Prolactin is a glycoprotein, similar in structure to growth hormone. It is a
milk producing hormone produced in the anterior lobe of the pituitary body.
Its role is to stimulate the mammary gland preparing the mother’s body for
lactation following childbirth.
During pregnancy, although prolactin levels rise, high levels of oestrogen
and progesterone prevent lactation. After childbirth the levels of oestrogen
and progesterone decrease triggering lactation. Through breast feeding
raised prolactin levels causes annovulation and amenorrhoea. Prolactin
influences gonadal function in both sexes, however normal prolactin levels
are slightly higher in woman than men.
Hyperprolactinaemia
The inhibitory control of the neurotransmitter dopamine is the most
important mechanism regarding prolactin secretion. Dopamine is secreted
from the hypothalamus into the pituitary venous system where it binds to
dopamine D2 receptors on prolactin secreting cells, thus inhibiting the
secretion of prolactin.
Persistent hyperprolactinaemia is usually due to a micro-adenoma of the
anterior pituitary. Dopamine receptor agonists including antipsychotic
drugs can also be responsible (Walker and Renwick, 1994).
The therapeutic action of Dopamine 2 receptor blockade is to reduce the
positive symptoms of psychosis such as perceptual and thought disorders
including hallucinations and delusions. It has long been known that
blockading this receptor with antipsychotic drugs, prescribed to treat these
symptoms, will often cause extra pyramidal side effects (EPSE) such as
parkinsonism, akathisia (motor restlessness), dystonias and tardive
dyskinesia. Indeed the emphasis on pharmacological research and
subsequent marketing in recent years with the introduction of atypical
(second generation) antipsychotics has been to eradicate EPSE in mental
health. However, blockade at this receptor is also responsible for elevated
prolactin levels causing endocrine problems including sexual dysfunction.
Although this mechanism has been recognised for more than a quarter of a
century (Beaumont, 1974) until recently this has attracted little clinical or
scientific interest, despite the fact that it is common, distressing and has the
potential for long term complications.
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Service users, when asked, consider the neuro endocrine effects of
antipsychotic drugs to be among the most undesirable of adverse effects,
leading to reduced levels of compliance with the medication they are
prescribed to treat their psychosis.
Table 1 below lists the physical effects associated with
hyperprolactinaemia:
TABLE 1: The clinical effects of hyperprolactaemia
EFFECT MALES FEMALES
Annovulation *
Infertility *
Amenorrhoea *
Decreased Libido * *
Gynaecomastia (breast enlargement) * *
Galactorrhoea (lactation) * *
Erectile dysfunction *
Ejaculatory dysfunction *
Azoospermia *
Weight gain * *
Research has consistently found that a great deal of service users with
psychosis (including schizophrenia) were found to have sexual dysfunction.
54% of male schizophrenics taking antipsychotics were experiencing
moderate to severe sexual dysfunction and 91% females reported
menstrual changes (Ghadirian, Chouinard and Annable, 1982).
As mentioned, a great cause of concern is the link between
hyperprolactinaemia and osteoporosis. Chronic low blood levels of sex
hormones results in increased reabsorption of calcium from bones, reduced
absorption of calcium from the gastrointestinal tract and increased loss of
calcium from the kidneys. This results in an overall reduction of calcium
content in bones resulting in oesteopinia or osteoporosis (Meaney and
O’Keene,2003). The Royal College of Physicians recommend women with
hyperprolactinaemia and a 12 month history of amenorrhoea should have
bone mineral density measurements. Further, hyperprolactinaemia may
increase the risk of breast cancer. It has been suggested that women
taking antipsychotic agents should undergo regular breast screening.
In generalised terms, individuals suffering from psychotic disorders such as
schizophrenia, have several risk factors that can predispose to
osteoporosis. They include reduced vitamin D, cigarette smoking, in some
cases excess alcohol and decreased level of exercise (particularly weight
bearing exercise). With the possibility of antipsychotic drug induced
hyperprolactinaemia in consequence their bone health is at risk of
impairment.
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Recognising and Managing Antipsychotic Drug Induced
Hyperprolactinaemia
The team I work with (Community Treatment Team) was commissioned in
1998 to work closely with service users in terms of medication
management. Currently we are five Registered Mental Nurses (RMNs) with
a specialist interest in psychotropic treatment strategies. We run several
community clinics and provide a domiciliary service for treatment and
monitoring. This includes depot, clozapine and mood stabiliser clinics
(Shaw, 2004). A large part of our work is side effect monitoring and
management. The aim of this is to reduce adverse effects and to enhance
service user outcomes by improving levels of concordance.
Using validated systematic rating scales such as the Liverpool University
Neuroceptic Side Effect Rating Scale (LUNSERS) (Day, 1995), we are able
to work closely with the service user to identify general areas of concern.
In order to gain more detailed information about the nature of unwanted
effects experienced, the use of more specific tools is essential, such as the
Abnormal Involuntary Movements Scale, (AIMS) the Barnes Akathisia
Scale, the Antipsychotic Non-Neurological Side Effect Rating Scale
(ANNSERS), the Arizona Sexual Experiences Scale, and so on. However,
I believe any rating scale (generalised or symptom specific) should be used
in combination with physical monitoring. For example, a person may not be
aware that he or she has developed drug induced neutropenia that can
lead to aggranulocytosis and thus be potentially fatal. A person may report
weight gain, but without an accurate, over time, record of weight and body
mass index the full extent of the problem cannot be assessed.
Table 2 lists some of the side effect management strategies used by the
Community Treatment Team:
TABLE 2: Interventions in adverse effect monitoring
1. Side Effect Rating Scale (Generalised) Lunsers, Sescam, Annsers,
UKU
2. Side Effect Rating Scale (Specific) AIMS, DISCUSS, Barnes Akathisia,
Arizona sexual experiences etc.
3. Blood Samples: Electrolytes and urea, thyroid function, full blood count
with differential, liver function, bone profile, random or fasting glucose,
prolactin level, fasting lipid profile, drug plasma level (e.g. for
Clozapine).
4. Physical Observations: Weight, height, BMI, pulse rate, laying/standing
blood pressure, respiration, temperature.
5. ECG (prescriber referral)
6. EEG (prescriber referral)
7. Relative/carer’s concerns/observations (with service user’s permission)
8. General observations (e.g. pallor, movement, speech, co-ordination,
etc.
9. Written/verbal communication to Consultant Psychiatrist, General
Practitioner and Care Co-ordinator.
Hyperprolactinaemia and antipsychotic drug use
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In terms of medication management, side effect monitoring is extremely
useful, but needs to be used in conjunction with treatment education,
current evidence for level of concordance and the service users’ beliefs and
wishes relating to their treatment. All this is undertaken at regular intervals
with the service users’ prescribed antipsychotics and is reported to the
prescriber (usually the Consultant Psychiatrist), the G.P. and the Care
Programme Approach (CPA) Care Co-ordinator.
The prescriber then has access to detailed and current information about
the service users antipsychotic drug use and is able to make more
evidence based prescribing decisions. The service user, having undergone
this process, is more able to make an informed choice about treatment,
validating their level of informed consent to treatment. The nurse who is
often administering these treatments is now able to continue his or her work
with the confidence that a thorough medication review has been
undertaken, reported and hopefully addressed.
For the purpose of this article I would like to focus on the neuroendocrine
adverse effects and how this problem can be addressed. Sexual
dysfunction, which is commonly associated with drug induced
hyperprolactinaemia, can be recognised at three levels:
The service user may report symptoms such as amenorrhea, erectile
dysfunction or reduced libido. Health care professionals may undertake
specific rating scales to identify problems, or physical tests (i.e. prolactin
level) may be taken to identify hyperprolactinaemia. Only the latter
intervention will diagnose hyperprolactinaemia with certainty. Prolactin
levels are obtained by venapuncture, ideally fasting or at least one hour
after food.
In Calderdale the range for males is 0 – 500 mIU/L and females 0 – 700
mIU/L (Milli international units per litre).
In Calderdale the Community Treatment Team has undertaken prolactin
level measurement for 194 patients between 2003 and 2005 (89 females,
105 males). Levels were all taken in the morning. If antipsychotic
treatment was altered, another baseline prolactin sample was obtained.
Informed consent was obtained following explanation of reason for sample
collection, all service users gave consent. 38% of service users were found
to have abnormal prolactin levels, 21% had levels above 1000 mIU/L
indicating significant hyperprolactinaemia.
Hyperprolactinaemia was significantly more prevalent in females than
males (females 52%, males 26%).
Significant hyperprolactinaemia (> 1000 mIU/L) was more prevalent in
females than males (females 38%, males 7%).
Of the 52% of females with abnormal values, 74% had values > 1000
mIU/L.
Although prolactin levels were above 1000 mIU/L in only 7% of males,
current evidence suggests that any high value (> 500 mIU/L) might
contribute to sexual dysfunction.
Michael Shaw
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These findings show that generally females taking antipsychotic agents are
more likely to develop hyperprolactinaemia than males, and further they are
more likely to show hyperprolactinaemia at significant levels than males.
Please see Table 3 for Hyperprolactinaemia and Gender results
TABLE 3: Hyperprolactinaemia and Gender results
FEMALES
N = 89
MALES
N = 105
TOTAL
N = 194
Prolactin (mIU/L) N % N % N %
ULN < 500 (Male)
< 700 (Female)
43 48 78 74 121 62
500/700 – 1000 12 13 20 19 32 16
1001 – 2000 22 25 5 5 27 14
> 2000 12 13 2 2 14 7
For males level 0 – 500 mIU/L or females 0 – 700 mIU/L were deemed to
be within normal range. For the purpose of this naturalistic study it was
decided that levels of 500 – 1000 mIU/L (males) / 700 – 1000 mIU/L
(females) were deemed to be borderline high. Levels 1001 – 2000 mIU/L
were deemed to be significantly high: that may need drug or dose
alterations. Levels above 2000 mIU/L were deemed to be extremely high:
may require referral to endocrinologist.
In terms of antipsychotic drugs and prolactin levels the following results
were obtained:
1. Risperidone (atypical antipsychotic) – As monotherapy 69% of
all service users were found to have elevated prolactin levels,
51% had levels above 1000 mIU/L. In terms of Risperidone
Consta (injectable preparation of Risperidone) 53% were found
to be hyperprolactinaemia, females had particularly high levels
of prolactin and 100% of female service users had levels above
1000 mIU/L, 4 out of 6 female service users had levels above
2000 mIU/L.
2. Amisulpride (atypical antipsychotic) – 100% of service users of
Amisulpride as monotherapy had elevated prolactin levels.
However numbers were small (seven) for this cohort.
3. Clozapine (atypical antipsychotic) – Only one service user (out
of 21) had elevated prolactin levels.
4. Olanzapine (atypical antipsychotic) – 6% of service users on
monotherapy had elevated prolactin levels.
5. Typical, or first generation atypicals, 36% had elevated prolactin
levels.
From this cohort of individuals prescribed antipsychotic drugs in
Calderdale, many were experiencing hyperprolactinaemia. We found that
two of the second generation drugs, Risperidone and Amisulphride, were
associated with high prevalence of hyperprolactinaemia than with the
Hyperprolactinaemia and antipsychotic drug use
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typical (or first generation drugs). Please refer to Table 4:
Hyperprolactinaemia by Agent
In monotherapy one individual taking Clozaril and one taking Olanzapine
were found to have had only borderline hyperprolactinaemia and for both
individuals repeat prolactin levels (without any drug alterations) taken some
weeks later, both showed normal levels, thus indicating that for these two
individuals hyperprolactinaemia was transient and in both cases
asymptomatic.
TABLE 4: Results: Hyperprolactinaemia by Agent
HP = Hyperprolactinaemia; N = Normal Level; AMI = Amisulpiride; TYP = Typical
(first generation Antipsychotics; OLANZ = Olanzapine; CONSTA – Risperidone
Consta (IMI Preparation); RISPoral – Risperidone Oral; CLOZ = Closapine;
ARI/QU = Aripiprozole and Quetiapine; MONO = Monotherapy; COMBO =
Combination Therapy (polypharmacy).
Attribution of hyperprolactinaemia to specific medications is complicated by
use of antipsychotic polypharmacy in 35/194 (18%) of service users.
The wide spread use of second generation antipsychotics within psychiatry
world wide was partly to reduce the prevalence of the movement disorder
side effect known as Extra Pyramidal Side Effects (National Institute of
Clinical Excellence, 2002). However in reality, for people taking these
drugs, one set of distressing and disabling adverse events have been
replaced with another : sexual dysfunction and endocrine disorder.
In our clinical practice, when hyperprolactinaemia is identified we have
found in general terms that addressing this issue tends not to be too
problematic for the service user, the prescriber or the mental health team.
In most cases a simple dose adjustment or switch to another antipsychotic
was found to effectively return prolactin levels to within normal parameters.
The following two case studies illustrate these points. The two case studies
have been anonymised in terms of any demographic information or
information that may compromise confidentiality, such as personal details.
Case Study (1)
Helen has a diagnosis a diagnosis of Bipolar II Disorder.
She attends the Psychiatric Outpatient Clinic three monthly for Consultant
Psychiatrist review and monitoring with the Community Treatment Team.
She does not have Sector Community Mental Health Team input as she
has been in remission for several years. At the time of her initial prolactin
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TOTAL
N = 194
AMI
N = 9
TYP
N = 112
OLANZ
N = 35
CONST
N = 17
RISPoral
N = 24
CLOZ
N= 23
ARI/QU
N = 3
HP N HP N HP N HP N HP N HP N HP N
MONO 7 7 27 83 1 16 9 17 15 18 1 21 0 3
COMBO 1 2 13 29 6 19 0 0 4 6 2 2 0 0
% in HP 89 36 20 53 79 13 0
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screen she was prescribed Carbamazepine 200mg b.d. and Risperidone
4mg per day.
In May 2003 she was seen in the Outpatient Clinic and reported
amenorrhea and reduced libido that had gradually worsened over several
months. A prolactin level, thyroid function and fasting blood glucose was
performed in addition to her routine Carbamazepine monitoring. Thyroid
function and glucose levels were within normal range ruling out sexual
dysfunction relating to thyroid changes or diabetes. Prolactin level was
1036 mIU/L. The range for females is 0 – 700 mIU/L. In response
Risperidone was stopped and Olanzapine 10mg was introduced. She was
seen again approximately 6 weeks later. Since the medication changes
she presented with no deterioration in terms of mental health. She had
started menstruating regularly quite quickly after the Risperidone was
stopped and she was beginning to experience an increase in libido. A
prolactin level taken at this time was 113 mIU/L (within normal range).
Gradually over time this lady’s libido returned to normal (for her) and by
January 2005 she was discharged from the Outpatient Clinic back to
Primary Care. Initially her level of sedation had increased when starting
Olanzapine but this was fairly short lived. She did not experience any
weight gain or glucose tolerance changes. Using a combination of early
warning signs work and pharmacological treatments, she has remained
well in terms of mental health.
This case study illustrates that for many individuals experiencing
psychotropic drug induced hyperprolactinaemia, management can be fairly
simple, in this case involving switching to an alternative antipsychotic drug,
with no risk of relapse or an increase in adverse affects.
Case Study (2)
Peter has a diagnosis of Paranoid Schizophrenia.
He attends the Psychiatric Outpatient Clinic for three monthly Consultant
Psychiatrist’s reviews and the Depot Clinic at the same venue.
Peter experiences ongoing psychotic symptoms, including persecutory
delusional ideas and auditory hallucinations. However, these symptoms
have decreased in frequency and intensity prior to transfer and he felt that
most importantly he had learnt to cope with impact of symptoms through
“creative distraction” and socialisation. Initially he had minimal activities,
but was in regular contact with his elderly parents and the Community
Mental Health Team involved in his care.
From January to July 2003 his medication package was Olanzapine 10mg
daily and Depixol 20mg fortnightly. Routine blood monitoring in July 2003
was as follows:
FBC (all normal); Thyroid Function (normal); LFT (normal) and a Prolactin
level of 728 mIU/L (range for males 0 – 500). At this point he was reporting
erectile dysfunction and enlarged “breasts” (however no galactorhoea). A
LUNSERS (Liverpool University Neuroleptic Side Effect Rating Scale) was
initiated with the following user report – dry mouth, constipation, reduced
libido and tremor.
Hyperprolactinaemia and antipsychotic drug use
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In an outpatient review the above was discussed and all involved, including
Peter, agreed a medication change was indicated. Therefore, the
Olanzapine dose was kept at 10mg per day with the Depixol frequency
changed from two to four weekly. It was decided to postpone the addition
of an antimuscarinic due to existing anticholinergic effects and the
possibility of tremor reduction through dose reduction of the Depixol.
Some months later he was reviewed again in the outpatient clinic. The
extent of psychotic symptoms described above were now practically gone
and he described himself as currently having no mental health problems,
despite the reduction of total antipsychotic dose.
A prolactin level was performed – 223 mIU/L – which was now within range
for males. He was no longer experiencing sexual dysfunction or known
endocrine disturbances. The Parkinsonism tremor had also stopped.
Some time later the depot medication was stopped completely and he
remains asymptomatic and functioning well on Olanzapine 10mg daily.
Again, this case illustrates in general terms the case of reducing prolactin
levels to an acceptable level with sensitive medication management. In this
case dose reduction of the drug probably responsible for the
hyperprolactinaemia was the effective strategy.
These case studies show that for most service users experiencing
hyperprolactinaemia, medication management strategies will be effective in
returning prolactin levels to normal, increasing psychotic symptomology.
Not all of our service users who have reported sexual dysfunction, such as
libido reduction, erectile problems or problems with orgasm, when tested
for prolactin level have elevated prolactin levels, some other causal factor is
involved. We screen for thyroid dysfunction and blood glucose
abnormalities as both conditions can affect sexual functioning. Other
physical or psychological factors are involved. In this case we refer to
colleagues in the sexual health field, often with successful outcomes. This
is only a small minority of individuals, and in very general terms for people
experiencing sexual dysfunction who are taking antipsychotic drugs
hyperprolactinaemia is the usual cause.
Key Learning Outcomes
1) Hyperprolactniaemia is a relatively common complication of
prescribed antipsychotic drug use. It causes the extreme distress
of endocrine disturbances, including sexual dysfunction.
2) Research shows that sustained hyperprolactinaemia is linked with
osteoporosis, with long term health care issues to the individual,
service providers and ultimately the health of the nation.
3) Many individuals with prolactin elevation may be asymptomatic in
terms of sexual dysfunction. Therefore, they may go undiagnosed
for hyperprolacrinaemia. Routine prolactin monitoring by
venapuncture will enable the prescribing clinician to make a
diagnosis of hyperprolactinaemia and treat.
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4) For the majority of individuals with drug induced
hyperprolactinaemia the condition is easily managed. For many
dose reduction, or drug change, will eradicate the problem with no
detriment to mental Health.
Conclusion
National Guidelines, including the Maudsley Prescribing Guidelines (Taylor,
Paton and Kerwin, 2003) recommend robust treatment pathways for the
treatment of hyperprolactineimia. However, not all locality trusts are
advocating prolactin monitoring and treatment as standard base line clinical
practice for their service users.
I believe that this should form part of the base line assessment procedure
for any individual prescribed antipsychotic treatment, especially the drugs
identified as strongly associated with hyperprolactinaemia. We have also
found that prolactin monitoring also allows early identification of prolactin
elevating conditions. One of our service users is currently being treated for
a prolactin secreting tumour that was asymptomatic at the time of the base
line prolactin test we undertook. It has become much clearer to me that
effective medication management in mental health requires much more
than a simple two page side effect assessment. Increasingly we are
required to undertake physical assessments including blood tests to identify
adverse effects that may not be symptomatic or recognised by the person
taking the drug or the healthcare professionals responsible for monitoring
the effects of medication.
Medication management interventions, including prolactin monitoring, will
improve medication concordance, thus minimising the risk of psychotic
relapse due to discontinuation, reduce the impact of sexual and endocrine
problems on the individual and minimise the risk of further long term
complications such as osteoporosis.
Hyperprolactinaemia and antipsychotic drug use
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MENTAL HEALTH AND LEARNING
DISABILITIES
RESEARCH AND PRACTICE
EDITORIAL BOARD MEMBERS
We are currently recruiting new members of the Editorial
Board.
We are looking for people with the following experience
and ability:
• Research
• Publishing papers
• Ability to read, critically appraise and review papers
• Organisational skills and ability to work to deadlines
• Able to communicate clearly with authors
• Able to attend at least 4 meetings per annum (meetings
usually take place in Huddersfield)
If you think that you fit the profile, please write to the
Editorial Board, C/o the Journal Administrator, Central
Services Building CS14/03, University of Huddersfield,
Queensgate, Huddersfield, HD1 3DH or e mail:
a.holmes@hud.ac.uk, outlining your experience and
reasons for wanting to apply.
We particularly welcome applications from service users
and carers.
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ANNUAL RESEARCH CONFERENCE 
 
Thursday 11th May 2006 10.00 am – 3.00 pm 
Education Centre, Fieldhead 
Wakefield  
The programme includes: 
Keynote speech – Steve Shrubb Director NIMHE NE 
Workshop sessions to include: 
! Access to & Coordination of Services 
! Developing & Applying the Evidence Base in 
Service Design & Delivery 
! Involving service users in Service Delivery 
 
Poster presentations 
If you would like to book a place please fill in a form or 
contact: 
Nicola Roberts 
Research and Development, 
Fieldhead, Wakefield 
Tel: 01924 328601  
E mail: Nicola.roberts@swyt.nhs.uk 
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Critical Appraisal
A half-day workshop
Critical Appraisal skills enable you to systematically assess the trustworthiness,
relevance and results of published papers. By the end of the session, participants
will have the necessary skills critically appraise research evidence about
effectiveness in order to promote evidence-based practice.
FIELDHEAD HOSPITAL, WAKEFIELD Wednesday 5th April 2006
Involving service users and carers in
research and evaluation
Aimed at any healthcare professional involved in research or evaluating a service,
this one day seminar involves researchers, managers and service users/patients
themselves in exploring ways of effectively including all stakeholders in designing
meaningful and valid projects.
Fieldhead Hospital, Wakefield Friday 5th May 2006
Clinical Trial
Co-ordination
A half day programme looking at the background requirements that underpin a
Clinical Trial within a NHS setting. By the end of the session participants will have
an introduction to ICH/GCP, role of monitor/sponsor/ research nurse. We will also
be looking at the principles of EU directives and the role they play into running a
Clinical Trial.
HUDDERSFIELD ROYAL INFIRMARY Thursday 17th May 2006
“From Bright Idea To Funded Proposal”
A one-day training course designed to enable participants to turn an idea for
research into a viable question, an introduction to the principles of research and
how to get that necessary funding for your project.
CALDERDALE ROYAL HOSPITAL 23rd May 2006
For further information on any of the courses please contact the HRI R&D
Department.
Telephone: 01484 347007. Email: R&D@cht.nhs.uk
RESEARCH SKILLS PROGRAMME
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Do you want to improve the lives of 
people who have a learning disability? 
 
 
We offer a wide range of exciting 
courses to suit your learning and 
development needs. 
Renowned for its friendly
environment and
excellent teaching record
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